TrialBMC infectious diseases2025

Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults.

Zhili Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.